Elekta presents Gamma Knife data as fair value for Elekta stock falls to SEK 86.58

Published on 10/13/2026 at 03:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 revenue fell 3.00 percent to SEK 3.54 billion in fiscal 2026/27. For Elekta stock, gross margin reached 42.60 percent before November 25 results.

Key points in brief

Elekta presented phase 2 Gamma Knife data for patients with up to 50 brain metastases on September 29, 2026.
Fair value was cut from SEK 92.79 to SEK 86.58 in a September 18 analyst update.
First-quarter revenue fell 3.00 percent to SEK 3.54 billion, while adjusted gross margin reached 42.60 percent.
Elekta's next report is scheduled for November 25, 2026, followed by a February 25, 2027 report.

Isometrische 3D-Grafik einer Wertschöpfungskette von Labor bis Patientenbett — Isometrische 3D-Illustration der Wertschöpfungskette veranschaulicht den Weg von Forschung bis Patientenversorgung bei Elekta AB SE0000163628, Illustration mit AI erstellt.

Elekta presented new phase 2 Gamma Knife data for patients with up to 50 brain metastases on September 29, 2026, while an analyst update cut fair value from SEK 92.79 to SEK 86.58. The clinical announcement and the valuation revision frame Elekta stock around evidence of treatment expansion and the need to restore operating growth.

Gamma Knife reaches 50 metastases

According to Elekta on September 29, 2026, the study covered patients with 5 to 50 brain metastases and showed favorable memory performance two months after treatment. Investigators reported no difference in time to meaningful cognitive decline between patients with 21 to 50 metastases and those with 5 to 20 metastases.

The result matters commercially because Elekta said more than 2 million patients are treated with its solutions each year across 130 countries. The release also links Gamma Knife to focal treatment that can limit radiation exposure to healthy brain tissue, although it states that further comparative investigations are needed.

Three dated operating signals

On September 15, 2026, Elekta's chief executive bought 200,000 shares, according to Affarsvärlden. On September 28, 2026, Elekta Unity data covered 123 patients treated for localized pancreatic cancer, as reported by Simply Wall St. The September 29 Gamma Knife release then added the 50-patient metastasis threshold.

What does the margin signal mean?

Elekta's first-quarter fiscal 2026/27 revenue fell 3.00 percent year over year to SEK 3.54 billion, while adjusted gross margin rose to 42.60 percent from 37.00 percent, according to Stock Sentinel on September 15, 2026. The same report said adjusted EBIT increased 68.00 percent to SEK 395.00 million, showing a sharp split between weaker revenue and better profitability.

That split explains the valuation debate. The September 18 update from Simply Wall St described fair value moving from SEK 92.79 to SEK 86.58, alongside a revised revenue-growth assumption of 5.57 percent. For investors, the key test is whether margin gains can offset the slower top line.

November report sets next test

Elekta's next quarterly report is scheduled for November 25, 2026, and the following report is listed for February 25, 2027, according to Affärsvärlden. Those dates give the market two checkpoints for revenue, margins and evidence that the clinical pipeline is translating into demand. The further course of trading is shown by the continuously updated real-time quote of Elekta stock.